Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Prescribing information notes that semaglutide- and tirzepatide-treated patients may have increases in amylase or lipase without pancreatitis and that the meaning of an isolated increase may be uncertain
CT-388 could potentially fit into the treatment paradigm if the following criteria based on clinical studies are met: Efficacy: CT-388 should demonstrate significant weight loss that is sustained over a longer-term period, as obesity requires chronic management
In clinical trials, people who used semaglutide lost an average of 10-15% of their body weight
If the remaining trials hold, it will be a real addition to obesity medicine, likely available late 2026 at the earliest
If you're comparing this against a different GLP-1 medication, our tirzepatide calculator guide follows the same calculation structure
US$ 21.74
US$ 25.55
US$ 28.56
